Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Anti-CDH17 CAR-T cells

Phase 1Cell therapy

SShanghai Pudong Hospital

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

CDH17-Positive Advanced Solid TumorsRecruiting

CDH17-Positive Advanced Malignant Solid TumorsRecruiting

CDH17-Positive Advanced Solid TumorsPhase 1

Recruiting

CDH17-Positive Advanced Malignant Solid TumorsPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

CDH17-Positive Advanced Solid Tumors

NCT06820424

Clinical

Trials by Indication[1]

CDH17-positive Advanced Malignant Solid Tumors1 trial

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Recruiting·SShanghai Pudong Hospital·Phase 1·NCT06501183·17 enrolled

CDH17-positive Advanced Solid Tumors1 trial

Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors

Recruiting·—·Phase 1·NCT06820424·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-CDH17 CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-CDH17 CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-CDH17 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pudong Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SShanghai Pudong Hospital

Related News